Amphotericin B (AmB) is a polyene antifungal agent used widely for systemic fungal infections. Infusion-related side effects, nephrotoxicity, and dyselectrolytemia are well-known adverse effects with the use of this drug. Liposomal preparation of AmB has less adverse events. However, ototoxicity due to AmB is scarcely mentioned in the literature. We report a case of disseminated histoplasmosis who was treated with liposomal amphotericin B (LAmB) and developed hearing loss during the treatment, which recovered after discontinuing the drug. This is a rare adverse effect of LAmB and reported only once from India, to the best of our knowledge.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265420 | PMC |
| http://dx.doi.org/10.4103/0253-7613.316948 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Amphotericin B Liposomal Lock Therapy in Fungal Peritonitis in a Patient With Peritoneal Dialysis: Regarding a Challenging Case].
Rev Med Chil
September 2024
Unidad de Diálisis Peritoneal, Departamento de Nefrología, Pontificia Universidad Católica de Chile, Santiago, Chile.
Fungal peritonitis is a rare complication associated with peritoneal dialysis, whose standard management consists of systemic antifungal therapy associated with early removal of the peritoneal dialysis catheter. This report describes and analyzes the use of lock therapy with intracatheter liposomal amphotericin B in a clinical case of fungal peritonitis.
View Article and Find Full Text PDFAuricular Mucormycosis: Comprehensive Literature Review.
Ear Nose Throat J
January 2025
Department of Otorhinolaryngology, Al Mouwasat University Hospital, Damascus University, Damascus, Syria.
Auricular mucormycosis is an exceptionally rare and aggressive fungal infection primarily affecting immunocompromised individuals, particularly those with poorly controlled diabetes. This report presents the case of a 54-year-old diabetic woman with isolated auricular mucormycosis and facial nerve palsy. The patient developed right auricular edema, necrosis, and severe pain, progressing over 10 days, with no history of trauma.
View Article and Find Full Text PDFContribution of epidermal growth factor (EGF) in the treatment of cutaneous leishmaniasis caused by Leishmania major in BALB/c mice.
PLoS Negl Trop Dis
January 2025
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Cutaneous leishmaniasis (CL) is a tropical disease that can cause chronic lesions and leave life-long scars, leading to social stigmatization and psychological disorders. Using growth factors and immunomodulatory agents that could accelerate wound healing and reduce the scar is highly demanded. Epidermal growth factor (EGF) plays an essential role in wound healing.
View Article and Find Full Text PDFEfficacy of liposomal amphotericin B in treating fungal meningitis in AIDS Patients: A review article.
Egypt J Immunol
January 2025
Department of Microbiology and Infection Prevention and Control Unit, Theodor Bilharz Research Institute, Giza 12411, Egypt.
Cryptococcal meningitis is an alarming fungal infection that usually affects the meninges surrounding the brain and spinal cord. The causative organism is Cryptococcus neoformans. Although this infection can occur in normal individuals, it is more often seen in patients with human immunodeficiency virus/acquired immunodeficiency syndrome.
View Article and Find Full Text PDFEfficacy and safety of posaconazole and liposomal amphotericin B use for prophylaxis of invasive fungal infections in a paediatric and young adult haemato-oncological population.
J Antimicrob Chemother
January 2025
Department for Women's and Children's Health-Division of Pediatric Infectious Diseases, Padua University Hospital, Padua, Italy.
Background: The prevention of invasive fungal infections (IFIs) is crucial for paediatric haemato-oncological patients. This study evaluates the clinical efficacy and side-effects of posaconazole and liposomal amphotericin B (L-AmB) as primary prophylaxis.
Materials And Methods: This cohort study included patients aged 3 months to 21 years who received posaconazole or L-AmB (5 mg/kg twice weekly) as prophylaxis from January 2017 to March 2022 at the Hemato-oncological Pediatric Unit, University Hospital of Padua, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!